IRVINE, CALIF. – December 2, 2024 – BioDuro-Sundia, a leading global contract research, development, and manufacturing organization, today announced the appointment of Alan Findlater as Chief Commercial Officer.
With over 25 years of senior commercial leadership experience in the life sciences and pharmaceutical services industries, Findlater brings a proven track record of leading high-performing teams of up to 150 professionals, managing complex product and service portfolios, building high-value partnerships with industry leaders including Amgen, Pfizer, and Roche, and executing successful strategic growth initiatives on a global scale.
“We are thrilled to welcome Alan Findlater to the BioDuro-Sundia executive team,” said Dr. Armin Spura, CEO of BioDuro-Sundia. “Alan’s vast experience and successful track record in the life sciences industry will be invaluable as we continue to enhance our commercial strategy, drive commercial success, and deliver innovative client-centric solutions that strengthen our market leadership.”
Findlater holds a bachelor’s in chemistry from the University of Strathclyde and an MBA from Warwick Business School, both in the U.K.
About BioDuro-Sundia
BioDuro-Sundia, an Advent portfolio company, is a CRDMO with a 28-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, with over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product.
Media Enquiries
Christina Coby, Marketing Manager
BioDuro-Sundia
Email: christina.coby@bioduro-sundia.com
Mobile: +1 (619) 414 7409
Chris HallingOrientation
MarketingEmail: chris.halling@orientation.agency
Mobile: +44 (0)7580 041073
